IRIS
BILO', Maria Beatrice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.146
EU - Europa 2.429
AS - Asia 2.377
SA - Sud America 417
AF - Africa 65
OC - Oceania 7
Totale 14.441
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.066
SG - Singapore 1.221
HK - Hong Kong 518
RU - Federazione Russa 476
IE - Irlanda 420
BR - Brasile 366
IT - Italia 355
CN - Cina 334
SE - Svezia 260
DE - Germania 242
UA - Ucraina 211
GB - Regno Unito 127
FR - Francia 105
VN - Vietnam 90
IN - India 79
FI - Finlandia 44
PL - Polonia 39
CA - Canada 38
NL - Olanda 35
ES - Italia 33
MX - Messico 32
CI - Costa d'Avorio 29
JP - Giappone 24
AT - Austria 23
AR - Argentina 20
BE - Belgio 19
BD - Bangladesh 18
ZA - Sudafrica 15
IQ - Iraq 14
LT - Lituania 10
MA - Marocco 10
TR - Turchia 10
SA - Arabia Saudita 8
UZ - Uzbekistan 8
PK - Pakistan 7
AU - Australia 6
CO - Colombia 6
KR - Corea 6
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
VE - Venezuela 5
CZ - Repubblica Ceca 4
DK - Danimarca 4
EC - Ecuador 4
ID - Indonesia 4
IL - Israele 4
CL - Cile 3
HN - Honduras 3
HU - Ungheria 3
JO - Giordania 3
NG - Nigeria 3
RS - Serbia 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AL - Albania 2
AM - Armenia 2
AZ - Azerbaigian 2
BH - Bahrain 2
DZ - Algeria 2
EE - Estonia 2
GR - Grecia 2
GY - Guiana 2
HR - Croazia 2
KZ - Kazakistan 2
LB - Libano 2
NP - Nepal 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
SR - Suriname 2
BG - Bulgaria 1
CH - Svizzera 1
DM - Dominica 1
EG - Egitto 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
IR - Iran 1
JM - Giamaica 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
MN - Mongolia 1
MY - Malesia 1
NO - Norvegia 1
NR - Nauru 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
TN - Tunisia 1
UY - Uruguay 1
Totale 14.441
Salva come PNG Salva come JPEG
Città #
Des Moines 1.770
Chandler 1.018
Singapore 881
Ashburn 683
Fairfield 535
Hong Kong 512
Dallas 468
Jacksonville 455
Dublin 418
Houston 334
Boardman 277
Wilmington 248
Woodbridge 248
Seattle 219
Cambridge 216
Lawrence 163
Princeton 163
San Mateo 142
Ann Arbor 123
The Dalles 105
Los Angeles 104
New York 101
Moscow 91
Redmond 87
Beijing 86
San Diego 65
Washington 60
Munich 52
Pune 50
Chicago 40
São Paulo 40
Ho Chi Minh City 39
Hefei 34
London 34
Abidjan 29
Warsaw 28
Turku 26
Nuremberg 25
Stockholm 25
Columbus 24
Santa Clara 24
Council Bluffs 21
Milan 21
Tokyo 21
Montreal 20
San Francisco 20
Ancona 19
Centro 19
Salt Lake City 19
Hanoi 18
Rome 18
Brussels 16
Helsinki 16
Phoenix 16
Guangzhou 15
Manchester 15
Orem 14
Amsterdam 13
Boston 13
Brooklyn 13
Falls Church 13
Kilburn 13
Mexico City 13
Norwalk 13
Buffalo 12
Cedar Knolls 12
Chennai 12
Shenzhen 10
Charlotte 9
Johannesburg 9
Miami 9
Shanghai 9
St Petersburg 9
Atlanta 8
Baghdad 8
Brasília 8
Denver 8
Elk Grove Village 8
Querétaro 8
Wuhan 8
Belo Horizonte 7
Gatchina 7
Porto Alegre 7
Rio de Janeiro 7
Tampa 7
Tashkent 7
Toronto 7
Vienna 7
Dhaka 6
New Bedfont 6
Pescara 6
Prescot 6
Riyadh 6
Squinzano 6
Turin 6
Ankara 5
Duque de Caxias 5
Florence 5
Hounslow 5
Lancaster 5
Totale 10.691
Salva come PNG Salva come JPEG
Nome #
Anaphylaxis in Elderly Patients-Data From the European Anaphylaxis Registry 249
Idiopathic anaphylaxis 221
The roadmap for the Allergology specialty and allergy care in Europe and adjacent countries. An EAACI position paper 221
Insights from comparison of serum IgG4 between T2-eosinophilic asthma and eosinophilic granulomatosis with polyangiitis/idiopathic hypereosinophilic syndrome 207
Diagnosing, managing and preventing anaphylaxis: Systematic review 157
Rhinopharyngoscopy, computed tomography and magnetic resonance imaging 148
Anaphylaxis 140
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19 133
Safety and Adherence to Venom Immunotherapy During COVID-19 Pandemic 131
Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma 129
Anaphylaxis in children and adolescents: The European Anaphylaxis Registry 125
Basal Tryptase High Levels Associated with a History of Arterial Hypertension and Hypercholesterolemia Represent Risk Factors for Severe Anaphylaxis in Hymenoptera Venom-Allergic Subjects over 50 Years Old 125
Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy) 124
Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice? 122
Diagnosis of Immediate-Type ß-Lactam Allergy In Vitro by Flow-Cytometric Basophil Activation Test and Sulfi doleukotriene Production: a Multicenter Study. 120
Development of a model care pathway for the management of Hymenoptera venom allergy: Evidence-based key interventions and indicators 119
Clinical aspects of hymenoptera venom allergy and venom immunotherapy 118
Anaphylaxis to baobab fruit: The paradox of “natural healthy food” 117
Why are allergens not detected in the bronchoalveolar lavage fluid of patients undergoing fiberoptic bronchoscopy? Possible explanations 117
In vivo diagnosis of allergic diseases - allergen provocation tests 115
Fatal anaphylaxis in Italy: Analysis of cause-of-death national data, 2004-2016 113
Allergen immunotherapy for insect venom allergy: protocol for a systematic review 109
Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry 109
Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry 108
Anaphylaxis caused by Hymenoptera stings: from epidemiology to treatment 107
Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes 107
Safety of a 2-day ultrarush immunotherapy in vespid allergic patients: Focus on elevated serum tryptase 106
The role of component-resolved diagnosis in Hymenoptera venom allergy 106
Advances in Hymenoptera venom immunotherapy 106
Detection of Gibberellin-Regulated Protein (Peamaclein) Sensitization among Italian Cypress Pollen-Sensitized Patients 106
Large local reactions to Hymenoptera stings: outcome of re-stings in real-life 105
Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies 104
World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis 103
Prevention and treatment of hymenoptera venom allergy: Guidelines for clinical practice 103
European hornet (Vespa crabro) sting: a new risk factor for life-threatening reaction in hymenoptera allergic patients? 103
Epidemiology of hymenoptera allergy 102
Is diet partly responsible for differences in COVID-19 death rates between and within countries? 102
Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis 101
A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study 100
Oxytocin: a likely underestimated risk for anaphylactic reactions in delivering women sensitized to latex 99
Phenotype and risk factors of venom-induced anaphylaxis: a case-control study of the European Anaphylaxis Registry 99
Editorial: Anaphylaxis – A Distinct Immunological Syndrome, but How Much Do We Really Understand? 98
World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings 98
Bonifazi F. Epidemiology of Hymenoptera sting anaphylaxis 96
ANCA-negative EGPA: only eosinophils without vasculitis? Insights from anti-T2 biologics 95
Contraindications to immunotherapy: A global approach 95
Antigen 5 Allergens of Hymenoptera Venoms and Their Role in Diagnosis and Therapy of Venom Allergy 95
Efficacy of a single dose of omalizumab for the prevention of ethylene oxide intraoperative anaphylaxis 94
Immunotherapy for hymenoptera venom allergy: too expensive for European health care? 94
CAP-Inhibition, Molecular Diagnostics, and Total IgE in the Evaluation of Polistes and Vespula Double Sensitization 93
Risk Factors and Characteristics of Biphasic Anaphylaxis 93
Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper 93
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 92
Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation? 92
Shedding Light on the Venom Proteomes of the Allergy-Relevant Hymenoptera Polistes dominula (European Paper Wasp) and Vespula spp. (Yellow Jacket) 92
Shortness of interval between two stings as risk factor for developing Hymenoptera venom allergy 92
Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper 92
Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy 92
Diagnosis of Hymenoptera venom allergy 92
2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis 91
EAACI anaphylaxis guidelines: Systematic review protocol 90
COVID-19 lockdown, personal protective equipment, hyper-hygiene and allergy 90
Hymenoptera Venom Allergy: Management of children and adults in clinical practice 89
Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control? 89
Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase 89
High adherence to hymenoptera venom subcutaneous immunotherapy over a 5-year follow-up: A real-life experience 88
World Allergy Organization anaphylaxis guidelines: Summary 88
Congruence between international guidelines and mite specific immunotherapy prescribing practices 88
The natural history and epidemiology of insect venom allergy: clinical implications 88
Hymenoptera Venom Immunotherapy: How to Safely Switch to the Same Venom From a Different Manufacturer 87
High long-term efficacy of venom immunotherapy after discontinuation 87
Efficacy of an air‐cleaning device equipped with a high efficiency particulate air filter in house dust mite respiratory allergy 86
Anisakis hypersensitivity in Italy: prevalence and clinical features: a multicenter study. 86
International consensus on (ICON) anaphylaxis 85
Hyposensitization therapy of Parietaria-sensitive patients with a tyrosine adsorbed allergoid, Pollinex Parietaria (Bencard Parietaria) 85
Lysozyme, a new allergen in donkey's milk 84
Insect sting anoxic encephalopathy after stopping venom immunotherapy. 84
Mast cell diseases and the severity and course of intraoperative anaphylaxis 83
The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts 83
Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity 83
EAACI Molecular Allergology User's Guide 82
Ves v 5 can establish the diagnosis in patients without detectable specific IgE to wasp venom and a possible north-south difference in Api m 1 sensitization in Europe 82
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy 81
Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy 81
Treating venom allergy during COVID-19 pandemic 81
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper 80
Hymenoptera Venom Allergy - European Academy of Allergy and Clinical Immunology Monographs 80
Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal Basal serum tryptase concentrations 80
Intraoperative anaphylaxis: verba volant, scripta manent! 80
Common Variable Immunodeficiency in Elderly Patients: A Long-Term Clinical Experience 80
Epinephrine in Severe Allergic Reactions: The European Anaphylaxis Register 79
Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels 79
Adherence to the rhinitis management plan of allergic rhinitis 79
The dilemma of the negative skin test reactors with a history of venom anaphylaxis: will this always be the case? 78
European Polistes venom allergy 77
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients 77
Platelet-activating factor acetylhydrolase: A biomarker in Hymenoptera venom allergy? 77
Efficacy of mepolizumab in patients with concomitant severe eosinophilic asthma and severe chronic urticaria: an example of personalized medicine? 77
Anxiety/depression and impaired asthma control in adolescents. Is an increased basal cholinergic tone a possible link ? 76
Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity 76
Totale 10.229
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.393
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.393
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.055 0 0 0 0 0 113 114 180 191 143 221 93
2021/20221.200 61 235 18 35 21 69 46 94 106 75 132 308
2022/20234.055 228 212 169 261 177 1.998 1 167 588 23 166 65
2023/20241.392 268 39 119 139 223 271 23 46 7 53 19 185
2024/20252.735 100 232 100 74 63 174 207 94 809 210 257 415
2025/20262.608 342 397 414 512 711 232 0 0 0 0 0 0
Totale 14.746